Cardiovascular DiseasesNCT00064493
Modeling DNA Diversity in Reverse Cholesterol Transport
An observational study of Cardiovascular Diseases and Heart Diseases, run by The University of Texas Health Science Center, Houston.
Trial summary
To identify genetic variation in reverse cholesterol transport (RCT) and its role in cardiovascular disease and atherosclerosis. Read more about this study
- Who is it for?
- Ages 18 to 30 yearsHealthy volunteers can take part
- Conditions the study is for
- Cardiovascular Diseases, Heart Diseases, Atherosclerosis
- How many people
- 4,146 participants
- Where
- No sites listed yet
- Study dates
- Jun 2003to May 2008
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 30 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: The sample to be studied by this Collaborative Research Project Grants consists of 2007 African-Americans and 2139 European-Americans equally divided between males and females between 18-30 years of age at the time of entry into the Coronary Artery Risk Development in Young Adults (CARDIA) study in 1985.
No eligibility criteria
About this study
To identify genetic variation in reverse cholesterol transport (RCT) and its role in cardiovascular disease and atherosclerosis.
Read the detailed description
BACKGROUND:
The collaborative research project will address a major problem in genetic epidemiology, namely the development of strategies to rationally identify and select sites or combinations of sites for genotype-phenotype studies that will be most relevant for predicting and understanding the role of genes in physiological phenotypes. Knowledge could be advanced in both specific and general terms. The project will focus on the genetic architecture of 62 genes either known or hypothesized to have a role in cholesterol transport. The data and conclusions generated by this project will enrich our understanding of both the extant genetic variation in these genes and the functional or causative relationships between such variation and phenotypes measured at a variety of organizational scales (pathway, systemic and clinical outcome). The additional focus on environmental interaction terms will enhance understanding of specific gene x environment interactions in the cholesterol transport system. The project involves three collaborating grants: R01HL72810 to Eric A. Boerwinkle at the University of Texas School of Public Health; R01HL72905 to Charles F. Sing at the University of Michigan at Ann Arbor; and R01HL72904 to Andrew Clark at Cornell University in Ithaca, New York.
DESIGN NARRATIVE:
This Collaborative Research Project will model DNA diversity in Reverse Cholesterol Transport (RCT) by exploring the genetic basis underlying this pathway and its contribution to atherosclerosis risk and cardiovascular disease (CVD). Given the progress of the Human Genome Project and the development of laboratory and analytic resources, the delineation of a gene's complete genetic architecture and contribution to individual differences within a population becomes (theoretically) feasible. This study will explore the variation in 8 of 62 candidate genes that will be screened using a battery of single nucleotide polymorphisms (SNPs). The eight genes (and the 6-10 SNPs within each) will be chosen based upon association with a surrogate quantitative trait (using a cholesterol efflux assay). The genes will be exhaustively characterized by analysis of DNA sequence variation, linkage disequilibrium (LD), and haplotypes in samples from the community-based CARDIA study. Genotype-phenotype relationships will be determined using analytic methods that take advantage of population/evolutionary history, underlying complexity, and other innovative approaches.
Component 1 of this Collaborative Research Project under Eric Boerwinkle will generate a large amount of new data on complex patterns of variation in a substantial number of genes. A major objective is to develop methods for analyzing these data to find etiologically relevant aspects of variation. For each of 62 candidate genes, the initial responsibility of Component 2 under Andrew Clark is to analyze the distribution of single DNA site and haplotype variation in terms of the population processes responsible for that variation. The investigators will develop systematic methods to identify subsets of sites that most fully capture the haplotypic structure of the data and thereby reduce the dimensionality of the variation. These methods will be applied to haplotype and genotype variation in a population-based sample of 2007 African-Americans and 2139 European-Americans from the CARDIA study. Single nucleotide polymorphisms frequency spectra, linkage disequilibrium and the block-wise structure of haplotypes will be quantified and related to expectations of population genetic theory. Novel approaches to genotype-phenotype associations will be pursued, in close collaboration with Component 3, by testing the fit of the neutral site frequency spectrum to data stratified by phenotypic measures.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Atherosclerosis
- Medical subject headings
- Cardiovascular Diseases, Heart Diseases, Atherosclerosis
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jul 2003 (estimated)
- Study startJun 2003
- Primary completionMay 2008
- Study completionMay 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Cardiovascular DiseasesStudies of the same condition, open and under way.
- More trials run by The University of Texas Health Science Center, HoustonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 4,146 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Responsible party
- Principal investigator, Eric Boerwinkle, The University of Texas Health Science Center, Houston
- Investigators
- Eric Boerwinkle, Principal investigator, University of Texas School of Public HealthAndrew Clark, Principal investigator, Cornell UniversityCharles Sing, Principal investigator, University of Michigan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00064493
- Sponsor's protocol ID
- 1223
- Other IDs
- R01HL072810
- Status last verified
- Sep 2021
- First submitted
- 8 Jul 2003
- Last updated
- 1 Oct 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Hamon SC, Stengard JH, Clark AG, Salomaa V, Boerwinkle E, Sing CF. Evidence for non-additive influence of single nucleotide polymorphisms within the apolipoprotein E gene. Ann Hum Genet. 2004 Nov;68(Pt 6):521-35. doi: 10.1046/j.1529-8817.2003.00112.x.
PubMed 15598211Klos KL, Hamon S, Clark AG, Boerwinkle E, Liu K, Sing CF. APOA5 polymorphisms influence plasma triglycerides in young, healthy African Americans and whites of the CARDIA Study. J Lipid Res. 2005 Mar;46(3):564-71. doi: 10.1194/jlr.M400437-JLR200. Epub 2004 Dec 16.
PubMed 15604515
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Modeling DNA Diversity in Reverse Cholesterol Transport
- ClinicalTrials.gov ID
- NCT00064493
- Acronym / sponsor ID
- 1223
- Conditions
- Cardiovascular Diseases, Heart Diseases, Atherosclerosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 4,146 participants (actual)
- Lead sponsor
- The University of Texas Health Science Center, HoustonUniversity, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Study start
- Jun 2003
- Primary completion
- May 2008 (actual)
- Study completion
- May 2008 (actual)
- First posted
- 10 Jul 2003 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To identify genetic variation in reverse cholesterol transport (RCT) and its role in cardiovascular disease and atherosclerosis.
Detailed description
BACKGROUND:
The collaborative research project will address a major problem in genetic epidemiology, namely the development of strategies to rationally identify and select sites or combinations of sites for genotype-phenotype studies that will be most relevant for predicting and understanding the role of genes in physiological phenotypes. Knowledge could be advanced in both specific and general terms. The project will focus on the genetic architecture of 62 genes either known or hypothesized to have a role in cholesterol transport. The data and conclusions generated by this project will enrich our understanding of both the extant genetic variation in these genes and the functional or causative relationships between such variation and phenotypes measured at a variety of organizational scales (pathway, systemic and clinical outcome). The additional focus on environmental interaction terms will enhance understanding of specific gene x environment interactions in the cholesterol transport system. The project involves three collaborating grants: R01HL72810 to Eric A. Boerwinkle at the University of Texas School of Public Health; R01HL72905 to Charles F. Sing at the University of Michigan at Ann Arbor; and R01HL72904 to Andrew Clark at Cornell University in Ithaca, New York.
DESIGN NARRATIVE:
This Collaborative Research Project will model DNA diversity in Reverse Cholesterol Transport (RCT) by exploring the genetic basis underlying this pathway and its contribution to atherosclerosis risk and cardiovascular disease (CVD). Given the progress of the Human Genome Project and the development of laboratory and analytic resources, the delineation of a gene's complete genetic architecture and contribution to individual differences within a population becomes (theoretically) feasible. This study will explore the variation in 8 of 62 candidate genes that will be screened using a battery of single nucleotide polymorphisms (SNPs). The eight genes (and the 6-10 SNPs within each) will be chosen based upon association with a surrogate quantitative trait (using a cholesterol efflux assay). The genes will be exhaustively characterized by analysis of DNA sequence variation, linkage disequilibrium (LD), and haplotypes in samples from the community-based CARDIA study. Genotype-phenotype relationships will be determined using analytic methods that take advantage of population/evolutionary history, underlying complexity, and other innovative approaches.
Component 1 of this Collaborative Research Project under Eric Boerwinkle will generate a large amount of new data on complex patterns of variation in a substantial number of genes. A major objective is to develop methods for analyzing these data to find etiologically relevant aspects of variation. For each of 62 candidate genes, the initial responsibility of Component 2 under Andrew Clark is to analyze the distribution of single DNA site and haplotype variation in terms of the population processes responsible for that variation. The investigators will develop systematic methods to identify subsets of sites that most fully capture the haplotypic structure of the data and thereby reduce the dimensionality of the variation. These methods will be applied to haplotype and genotype variation in a population-based sample of 2007 African-Americans and 2139 European-Americans from the CARDIA study. Single nucleotide polymorphisms frequency spectra, linkage disequilibrium and the block-wise structure of haplotypes will be quantified and related to expectations of population genetic theory. Novel approaches to genotype-phenotype associations will be pursued, in close collaboration with Component 3, by testing the fit of the neutral site frequency spectrum to data stratified by phenotypic measures.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 30 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- The sample to be studied by this Collaborative Research Project Grants consists of 2007 African-Americans and 2139 European-Americans equally divided between males and females between 18-30 years of age at the time of entry into the Coronary Artery Risk Development in Young Adults (CARDIA) study in 1985.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2021.
- Background: PubMed 15598211Hamon SC, Stengard JH, Clark AG, Salomaa V, Boerwinkle E, Sing CF. Evidence for non-additive influence of single nucleotide polymorphisms within the apolipoprotein E gene. Ann Hum Genet. 2004 Nov;68(Pt 6):521-35. doi: 10.1046/j.1529-8817.2003.00112.x.
- Background: PubMed 15604515Klos KL, Hamon S, Clark AG, Boerwinkle E, Liu K, Sing CF. APOA5 polymorphisms influence plasma triglycerides in young, healthy African Americans and whites of the CARDIA Study. J Lipid Res. 2005 Mar;46(3):564-71. doi: 10.1194/jlr.M400437-JLR200. Epub 2004 Dec 16.
Related trials for Cardiovascular Diseases
RecruitingObservational study
Genetics of Type 2 Diabetes in West Africans
Hypertension, Diabetes
RecruitingObservational study
Atrial Fibrillation Patients Treated With Catheter Ablation
Atrial Fibrillation, Atrial Fibrillation Recurrent
RecruitingPhase 1
Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
AML, Multiple Myeloma
Active, not recruiting
Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension
Primary Aldosteronism, Resistant Hypertension
RecruitingPhase 2
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Multiple Myeloma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eric Boerwinkle principal investigator
University of Texas School of Public Health
Andrew Clark principal investigator
Cornell University
Charles Sing principal investigator
University of Michigan
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiovascular Diseases and Heart Diseases, run by The University of Texas Health Science Center, Houston.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00064493, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2021.